OUR MISSION

We are committed to developing improved therapies for the treatment of severe respiratory diseases. Our lead asset is inhaled imatinib (AER-901) for the treatment of pulmonary arterial hypertension.

OUR APPROACH

Our product development approach combines novel formulations of existing drugs with our inhalation technology for the treatment of severe respiratory diseases with high unmet need.

MANAGEMENT TEAM

Our management team brings together formulation, device development, clinical and commercial expertise.

BOARD OF DIRECTORS

Anne Whitaker, Chief Executive Officer and Director

John Patton, PhD, Director and Founder

Steve Thornton, Chairman, Chair of Compensation Committee

Adam Stern, Director

Bill Welch, Director

Kenneth B. Lee, Jr. Director, Chair of Audit Committee

CAREERS

Join us in our effort to develop a new generation of inhaled therapies.